Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study

J. Kanda, H. Hayashi, A. Ruggeri, F. Kimura, F. Volt, S. Takahashi, M. Labopin, S. Kako, K. Tozatto-Maio, S. Yano, G. Sanz, N. Uchida, M.T. Van Lint, S. Kato, M. Mohty, E. Forcade, H. Kanamori, J. Sierra, Y. Ohno, R. SaccardiT. Fukuda, T. Ichinohe, M. Takanashi, V. Rocha, S. Okamoto, A. Nagler, Y. Atsuta, E. Gluckman

Research output: Contribution to journalArticlepeer-review

Abstract

Large differences in patient and transplant backgrounds make it difficult to identify consistent prognostic factors of unrelated cord blood transplantation (UCBT) among different populations. Thus, we performed a collaborative study between Eurocord/ALWP-EBMT and JSHCT/JDCHCT. Adults with acute leukaemia who underwent a single UCBT were eligible. In total, 3764 and 1027 patients of the JSHCT/JDCHCT and Eurocord/ALWP-EBMT registries, respectively, were included. The median ages of the Japanese and European cohorts were 51 and 38 years, respectively. Three or more HLA mismatches were more frequently observed in the Japanese cohort. The median total nucleated cell (TNC) counts were 2.58 and 3.51 × 107/kg in the Japanese and European cohorts, respectively. Anti-thymocyte globulin was used in only 2% of the Japanese cohort compared with 65% of the European cohort. The 3-year overall survival (OS) was 41% in JSHCT/JDCHCT and 33% in Eurocord/ALWP-EBMT. In the multivariate analysis, TNC dose and HLA matching had no significant effect on OS in either cohort, whereas year of transplantation, age, and refined disease risk index affected OS in both cohorts. Despite considerable differences in characteristics between the Japanese and European cohorts, we observed similar prognostic factors affecting UCBT outcomes in adult patients with acute leukaemia in both registries. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.
Original languageEnglish
Pages (from-to)128-137
Number of pages10
JournalLeukemia
Volume34
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • busulfan
  • calcineurin inhibitor
  • HLA A antigen
  • HLA B antigen
  • HLA DR antigen
  • HLA DRB1 antigen
  • melphalan
  • methotrexate
  • mycophenolate mofetil
  • thiotepa
  • thymocyte antibody
  • acute graft versus host disease
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • adult
  • age
  • aged
  • Article
  • cancer free survival
  • cancer incidence
  • cancer prognosis
  • cancer radiotherapy
  • cancer recurrence
  • cancer risk
  • cause of death
  • cell count
  • chronic graft versus host disease
  • controlled study
  • cord blood stem cell transplantation
  • European
  • female
  • HLA matching
  • human
  • Japanese (people)
  • major clinical study
  • male
  • multinuclear cell
  • myeloablative conditioning
  • overall survival
  • priority journal
  • radiation dose
  • recurrence risk
  • time to treatment
  • whole body radiation
  • disease free survival
  • Europe
  • Japan
  • middle aged
  • mortality
  • procedures
  • prognosis
  • treatment outcome
  • Adult
  • Aged
  • Cord Blood Stem Cell Transplantation
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Myeloid, Acute
  • Male
  • Middle Aged
  • Prognosis
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study'. Together they form a unique fingerprint.

Cite this